Gyroscope Therapeutics, Orbit Biomedical to merge

Gyroscope Therapeutics and Orbit Biomedical will merge to form one retinal gene therapy company, according to a press release.
Operating under the Gyroscope name, the company will have clinical, manufacturing and delivery capabilities.
“It is an exciting time to join Gyroscope with our first clinical study in patients with geographic atrophy due to dry AMD underway,” Gyroscope CEO Khurem Farooq said in the release. “By joining forces with Orbit, we can combine our expertise in developing gene therapies and our high-quality manufacturing processes with a surgical platform that

Full Story →